Back to Search
Start Over
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
- Source :
- Annals of Oncology, Annals of Oncology, Elsevier, 2019, 30 (8), pp.1370-1380. ⟨10.1093/annonc/mdz176⟩, Dipòsit Digital de la UB, Universidad de Barcelona, Annals of Oncology, 2019, 30 (8), pp.1370-1380. ⟨10.1093/annonc/mdz176⟩, Annals of Oncology, 30, 1370-1380, Annals of Oncology, 30(8), 1370-1380. Oxford University Press, Annals of Oncology, 30, 8, pp. 1370-1380
- Publication Year :
- 2019
- Publisher :
- HAL CCSD, 2019.
-
Abstract
- International audience; BACKGROUND: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data.METHODS: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated.RESULTS: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus ≤ upper limit of normal) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3 cm versus
- Subjects :
- Male
Uveal Neoplasms
0301 basic medicine
Oncology
Time Factors
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Medizin
Datasets as Topic
Phases of clinical research
CHOROIDAL MELANOMA
Kaplan-Meier Estimate
Metastasis
0302 clinical medicine
STAGE-IV MELANOMA
Prospective Studies
Prospective cohort study
Melanoma
Aged, 80 and over
Clinical Trials as Topic
survival benchmarks
Liver Neoplasms
TEMOZOLOMIDE
Hematology
Middle Aged
Prognosis
Progression-Free Survival
3. Good health
Benchmarking
Research Design
030220 oncology & carcinogenesis
CHEMOEMBOLIZATION TACE
Female
medicine.symptom
uveal melanoma
PHASE-II TRIAL
medicine.drug
Adult
medicine.medical_specialty
Adolescent
3122 Cancers
[SDV.CAN]Life Sciences [q-bio]/Cancer
LIVER METASTASES
Young Adult
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
Sex Factors
Metàstasi
Internal medicine
medicine
Humans
3125 Otorhinolaryngology, ophthalmology
Progression-free survival
[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs
COMBINATION
Aged
Temozolomide
L-Lactate Dehydrogenase
business.industry
Cancer
Alkaline Phosphatase
medicine.disease
Elevated alkaline phosphatase
meta-analysis
1ST-LINE TREATMENT
030104 developmental biology
trial design
INTRAARTERIAL
business
GEMCITABINE PLUS TREOSULFAN
Subjects
Details
- Language :
- English
- ISSN :
- 09237534 and 15698041
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology, Annals of Oncology, Elsevier, 2019, 30 (8), pp.1370-1380. ⟨10.1093/annonc/mdz176⟩, Dipòsit Digital de la UB, Universidad de Barcelona, Annals of Oncology, 2019, 30 (8), pp.1370-1380. ⟨10.1093/annonc/mdz176⟩, Annals of Oncology, 30, 1370-1380, Annals of Oncology, 30(8), 1370-1380. Oxford University Press, Annals of Oncology, 30, 8, pp. 1370-1380
- Accession number :
- edsair.doi.dedup.....cde8c096956be9a861c1223f6bc8c007